Biomedical and Healthcare Recombinant Protein Solutions

Biomedical and Healthcare Recombinant Protein Solutions
Product Description

Combines molecular engineering, host cell optimisation, expression system development, and process optimisation to address complex protein structures. The IgMax® platform enables production of pentameric IgM at high expression levels, with near‑complete pentamer assembly and excellent purity after downstream purification. Supports from early expression development to scale‑up and manufacturing.

Canton Biologics

  • Country/Region:
    Hong Kong
  • Founded:
    2016
  • On CPHI since:
    2026
  • Employees:
    250 - 499
Company types
CMO/CDMO
Specifications
  • CAS Registry Number
    N/A
  • Details
    Recombinant IgM, complex recombinant proteins, difficult‑to‑express proteins; applications in biomedicine, in vitro diagnostics, healthcare, and other high‑value fields.

  • Selling Points
    Customised for high‑difficulty proteins; full chain from gene synthesis to purification process.

  • Model
    IgMax® Platform for high‑yield pentameric IgM production
  • Supplied from
    China
  • Measured In
    Container

Canton Biologics

  • Country/Region:
    Hong Kong
  • Founded:
    2016
  • On CPHI since:
    2026
  • Employees:
    250 - 499
Company types
CMO/CDMO

More Products from Canton Biologics (2)

  • Biologics Development Solutions for Companion Animal Therapeutics

    Product Biologics Development Solutions for Companion Animal Therapeutics

    Leverages advanced expression technologies, optimised vectors, and flexible bioprocessing platforms to deliver scalable and cost‑efficient solutions tailored to companion animal biologics. Supports from early development to GMP manufacturing, with customisation for veterinary specific requirements.

  • Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins

    Product Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins

    Integrated development and manufacturing solutions combining molecular engineering, vector optimization, host cell engineering, and customized process development. The platform delivers high titers for mAb production, and DTEasy™ strategies have demonstrated significant yield improvements across various di...